KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer

KRAS mutations occur in 30–40% of all cases of human colorectal cancer (CRC). However, to date, specific therapeutic agents against KRAS-mutated CRC have not been developed. We previously described the generation of mouse models of colon cancer with and without Kras mutations (CDX2P-G22Cre;Apc(flox/...

Descripción completa

Detalles Bibliográficos
Autores principales: Niitsu, H, Hinoi, T, Kawaguchi, Y, Sentani, K, Yuge, R, Kitadai, Y, Sotomaru, Y, Adachi, T, Saito, Y, Miguchi, M, Kochi, M, Sada, H, Shimomura, M, Oue, N, Yasui, W, Ohdan, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007825/
https://www.ncbi.nlm.nih.gov/pubmed/27526107
http://dx.doi.org/10.1038/oncsis.2016.47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007825/
https://www.ncbi.nlm.nih.gov/pubmed/27526107
http://dx.doi.org/10.1038/oncsis.2016.47

Ejemplares similares